At the time of writing, Atara Biotherapeutics Inc [ATRA] stock is trading at $5.0, up 8.70%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The ATRA shares have gain 11.86% over the last week, with a monthly amount drifted -70.88%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Atara Biotherapeutics Inc [NASDAQ: ATRA] stock has seen the most recent analyst activity on January 13, 2026, when Canaccord Genuity downgraded its rating to a Hold but kept the price target unchanged to $6 for it. Previously, Mizuho downgraded its rating to Neutral on November 09, 2023, and dropped its price target to $1. On November 09, 2023, downgrade downgraded it’s rating to Neutral. Evercore ISI downgraded its rating to a In-line. Citigroup downgraded its rating to a Sell and reduced its price target to $3 on July 20, 2022. Stifel downgraded its rating to Hold for this stock on July 13, 2022, and downed its price target to $5. In a note dated July 13, 2022, JP Morgan downgraded a Neutral rating on this stock but restated the target price of $10.
For the past year, the stock price of Atara Biotherapeutics Inc fluctuated between $4.20 and $19.15. Currently, Wall Street analysts expect the stock to reach $15.5 within the next 12 months. Atara Biotherapeutics Inc [NASDAQ: ATRA] shares were valued at $5.0 at the most recent close of the market. An investor can expect a potential return of 210.0% based on the average ATRA price forecast.
Analyzing the ATRA fundamentals
According to Atara Biotherapeutics Inc [NASDAQ:ATRA], the company’s sales were 151.93M for trailing twelve months, which represents an -91.41% plunge. Gross Profit Margin for this corporation currently stands at 0.82% with Operating Profit Margin at 0.17%, Pretax Profit Margin comes in at 0.15%, and Net Profit Margin reading is 0.15%. To continue investigating profitability, this company’s Return on Assets is posted at 0.78, Equity is -0.42 and Total Capital is 2.17. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -1.6.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Atara Biotherapeutics Inc [NASDAQ:ATRA] has a current ratio of 1.02. Further, the Quick Ratio stands at 1.02, while the Cash Ratio is 0.32. Considering the valuation of this stock, the price to sales ratio is 0.24 and price to earnings (TTM) ratio is 2.28.
Transactions by insiders
Recent insider trading involved Panacea Innovation Ltd, 10% Owner, that happened on Jan 12 ’26 when 80554.0 shares were sold. 10% Owner, Panacea Innovation Ltd completed a deal on Jan 12 ’26 to buy 40000.0 shares. Meanwhile, President and CEO Nguyen AnhCo sold 2915.0 shares on Nov 17 ’25.
